{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Is Vaxcyte, Inc. technically bullish or bearish?
As of June 5, 2025, the market trend is mildly bearish, indicated by daily moving averages and Bollinger Bands, despite some bullish signals from the MACD and RSI, suggesting a cautious approach.
Who are in the management team of Vaxcyte, Inc.?
As of March 2022, the management team of Vaxcyte, Inc. includes Dr. Moncef Slaoui (Chairman), Mr. Grant Pickering (CEO, Co-Founder), and several directors: Ms. Halley Gilbert, Mr. Patrick Heron, Dr. Peter Hirth, Dr. Robert Hopfner, and Dr. Heath Lukatch. They oversee the company's strategic direction and operations.
What does Vaxcyte, Inc. do?
Vaxcyte, Inc. is a mid-cap vaccine company focused on developing vaccines for infectious diseases. As of March 2025, it reported a net profit loss of $141 million and has a market cap of approximately $4.34 billion.
How big is Vaxcyte, Inc.?
As of Jun 18, Vaxcyte, Inc. has a market capitalization of $4.34 billion, with net sales of $0.00 million and a net profit of -$509.62 million over the latest four quarters. As of Dec 24, the company has shareholder's funds of $3.31 billion and total assets of $3.53 billion.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
